Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
PD-1
cancer
checkpoint
inhibition
Journal
Immunotherapy advances
ISSN: 2732-4303
Titre abrégé: Immunother Adv
Pays: England
ID NLM: 101776979
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
09
2023
accepted:
20
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Immunotherapy treatment strategies have proven effective in a limited portion of patients, where identifying responders from non-responders to treatment remains a challenge. While some indications can be drawn from invasive biopsies, we need more accessible methods for predicting response and better correlates of response prior to starting therapy. Recent work has identified differences in immune composition at baseline in peripheral blood from melanoma patients responding to PD-1 blockade treatment. Through flow cytometric analysis of T cell receptors, phenotypical features of CD8+ and CD4+ T cells and Tregs could allow for the stratification of treatment response. Analysing T cells within peripheral blood could potentially allow for the stratification of PD-1 treatment response prior to therapy in different cancer settings.
Identifiants
pubmed: 38020310
doi: 10.1093/immadv/ltad026
pii: ltad026
pmc: PMC10676196
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ltad026Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest.
Références
Clin Cancer Res. 2019 Apr 1;25(7):2144-2154
pubmed: 30647082
Immunother Adv. 2023 Jan 06;3(1):ltad001
pubmed: 36818683
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Curr Hematol Malig Rep. 2018 Oct;13(5):383-395
pubmed: 30159703
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
J Hematol Oncol. 2021 Mar 19;14(1):45
pubmed: 33741032
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
Curr Opin Immunol. 2022 Feb;74:18-24
pubmed: 34619457
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
J Clin Invest. 2016 Sep 1;126(9):3447-52
pubmed: 27525433
Immunother Adv. 2022 Apr 08;2(1):ltac008
pubmed: 35919497
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Front Immunol. 2020 Oct 16;11:603157
pubmed: 33178229